Article

Roche shifts funding priorities

Pharmaceutical company Roche seems to be changing up its research focus. The company is pulling the plug on its HIV research program, and today offered more than $40 billion to buy up the 44% of biotech Genentech that it does not already own. A Roche spokesperson told linkurl:Chemical & Engineering News;http://pubs.acs.org/cen/news/86/i29/8629notw7.html that there are no drugs in the company's HIV drug pipeline that warrant further development. They had been developing antiretrovirals, all of w

Written byAndrea Gawrylewski
| 1 min read
Save for Later
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Pharmaceutical company Roche seems to be changing up its research focus. The company is pulling the plug on its HIV research program, and today offered more than $40 billion to buy up the 44% of biotech Genentech that it does not already own. A Roche spokesperson told linkurl:Chemical & Engineering News;http://pubs.acs.org/cen/news/86/i29/8629notw7.html that there are no drugs in the company's HIV drug pipeline that warrant further development. They had been developing antiretrovirals, all of which were still at the preclinical stage. The HIV researchers at Roche will be reassigned to other therapeutic areas, the spokesperson said. She added that Roche will continue to support the HIV therapies it already makes, including linkurl:Fuzeon,;http://www.the-scientist.com/2007/03/01/s60/1/ a cell fusion inhibitor, which the FDA approved in 2003. Meanwhile, Roche linkurl:announced today;http://www.roche.com/med-cor-2008-07-21b its offer of $89 per share to buy Genentech's remaining public shares. Roche currently owns 55.9% of all the biotech's shares. Andreas Theisen, a pharmaceutical analyst at WestLB Equity Markets in Germany, told linkurl:The New York Times;http://www.nytimes.com/2008/07/22/business/worldbusiness/22roche.html?_r=1&partner=rssnyt&emc=rss&referer=sphere_related_content&referer=sphere_related_content&oref=slogin the offer was "quite a departure" from Roche's traditional strategy. At a press conference today in Switzerland, Roche chairman Franz Humer said Genentech will keep operating as an independent research arm and keep "the operational freedom to maintain a high level of creativity and independent decision making."
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Join for free today
Already a member? Login Here
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Share

Related Research Resources

A menstrual cup and storage bag on a blue background

Collecting Insights into the Vaginal Microbiome and Menstrual Health

Article

DNA Genotek logo
An illustration of PFAS in the bloodstream.

Uncovering the Harmful Effects of PFAS Exposure on the Human Body

Infographic

An illustration of PFAS bubbles in front of a blue sky with clouds.

PFAS: The Forever Chemicals

Infographic

sartorius logo
Abstract paint splashes resembling viral particles on a colorful background.

Accelerating Pathogen Detection with Nanopore Sequencing

Whitepaper

Oxford Nanopore Technologies Logo
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Product News

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Graphic of amino acid chains folded into proteins

Expi293™ PRO Expression System: Higher Yields Across a Wider Variety of Proteins

Thermo Fisher Logo